----

| Delaware                                                          |                                             | 000-23143               |       | 13-3379479                       |
|-------------------------------------------------------------------|--------------------------------------------------|-------------------------|------------|----------------------------------|
| (State or other jurisdictionof incorporation)                     |                                             | (CommissionFile Number) |       | (IRS EmployerIdentification No.) |
|                                                              |                                             |                    |       |                             |
|                                                                   | 777 Old Saw Mill River Road, Tarrytown, New York |                    | 10591      |
|                                                                   | (Address of principal executive offices)         |                    | (Zip Code) |
| Registrant's telephone number, including area code (914) 789-2800 |
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---------------------------------------------------------------------------------------|
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|---|----------------------------------------------------------------------------------------|
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|---|--------------------------------------------------------------------------------------------------------|
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|---|--------------------------------------------------------------------------------------------------------|

----

| Item 2.01. | Completion of Acquisition or Disposition of Assets. |
|------------|-----------------------------------------------------|
| Item 9.01. | Financial Statements and Exhibits. |
|------------|------------------------------------|
| (a) | Pro forma financial information. |
|-----|----------------------------------|
| (d)         | Exhibits.                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|        |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Exhibit No. | Description                                                                                                                                                                                                                                                                                                                                                                                                                     |
|        |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 23.1        | Consent of BDO USA, LLP.                                                                                                                                                                                                                                                                                                                                                                                                   |
|             |                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 99.1*       | Consolidated Balance Sheets of Molecular Insight Pharmaceuticals, Inc. as of December 31, 2012 and 2011 (Successor), and the related Consolidated Statements of Operations, Changes in Stockholders' Equity (Deficit), and Cash Flows for the year ended December 31, 2012 (Successor) and for the period from June 1, 2011 to December 31, 2011 (Successor), and for the period January 1, 2011 to May 31, 2011 (Predecessor). |
|        |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 99.3        | Unaudited Pro Forma Combined Statements of Operations For The Three Months Ended March 31, 2013 And For The Year Ended December 31, 2012.                                                                                                                                                                                                                                                                                       |
| * |  Incorporated by reference to Amendment No. 1 to the April 4, 2013 filing referred to in the Explanatory Note. |
|---|---------------------------------------------------------------------------------------------------------------------|

----

|   | PROGENICS PHARMACEUTICALS, INC. |
|--------|---------------------------------|
|   | By:                             | /s/ ANGELO W. LOVALLO, JR. |
|   |                            | Angelo W. Lovallo, Jr. |
|   |                            | Vice President-Finance and Treasurer |
|   |                            | (Principal Financial and Accounting Officer) |